Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer Carbonate vs Renvela for Hyperphosphatemia in Hemodialysis CKD Patients
ChiCTR2100047153Phase 3Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sevelamer carbonate in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Serum phosphorus. Started May 2015; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2100047153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047153.